⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27149593 | 1.00 | — | — | |
| SCHEMBL29071067 | 1.00 | — | — | |
| SCHEMBL28116028 | 0.85 | LMNA (0.31) | — | |
| SCHEMBL873523 | 0.85 | — | — | |
| SCHEMBL21145 | 0.85 | — | — | |
| SCHEMBL4356648 | 0.85 | — | — | |
| SCHEMBL6352139 | 0.83 | — | — | |
| SCHEMBL2592648 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL18690254 | 0.83 | — | — | |
| SCHEMBL6669492 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146383-A1 | CYP11A1 INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海闻耐医药科技有限公司 | 2024-07-11 | — | — | WO | claimed |
| EP-3984994-B1 | SUBSTITUTED PIPERIDINE COMPOUND AS OREXIN TYPE 2 AGONIST FOR THE TREATMENT OF NARCOLEPSY | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-03 | — | — | EP | claimed |
| US-20240182406-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2024-06-06 | — | — | US | claimed |
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | claimed |
| CN-118019728-A | Compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2024-05-10 | — | — | CN | claimed |
| CN-117534668-A | Heterocyclic compounds useful as GLP-1 receptor agonists, compositions, formulations and uses thereof | 北京福元医药股份有限公司 | 2024-02-09 | — | — | CN | claimed |
| EP-4313947-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2024-02-07 | — | — | EP | claimed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | claimed |
| EP-3984994-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-04-20 | — | — | EP | claimed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | claimed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | claimed |
| US-9227969-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | claimed |
| CN-102449157-B | Process for the preparation of (3R)-hydr0xybutyl (3R) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase | ISIS INNOVATION | 2015-06-03 | — | — | CN | claimed |
| US-20150051209-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | claimed |
| WO-2015022662-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | WO | claimed |
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | claimed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | claimed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-0345073-A1 | Poly (3-(Substituted)-3(Hydroxymethyl) oxetane) and method of preparing same | ARIZONA BOARD OF REGENTS (US) | 1989-12-06 | — | — | EP | claimed |
| US-4833183-A | FILMS, FIBERS, MOLDING MATERIALS EXPLOSIVES | ARIZONA BOARD OF REGENTS (US) | 1989-05-23 | — | — | US | claimed |